Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer

Summary

Phase II study, randomized, open-label, multicentric, willing to establish the benefit of pursuing chemotherapy beyond 6 weeks for non progressive patients. The study will proceed in two successive phases : * non randomized phase in which all patients will undergo chemotherapy * second phase in which only non progressive patients are going to be randomized ("discontinuation design"). Patients that will show progression in their disease during the first 6 weeks will be released of the study

Timeline

Start

2018-08-20

Primary completion

2022-07-05

Completion

2022-07-05

Outcome

Outcome not reported

Stopped (Enrollment): “This decision was taken on June 20 2022 due to low recruitment over the past 4 years.”

Drugs

Indications